-
Mashup Score: 20MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling - PubMed - 4 month(s) ago
Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare and resistance ultimately emerges from residual tumor cells. Although several acquired resistance mechanisms have been reported …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling - PubMed - 4 month(s) ago
Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare and resistance ultimately emerges from residual tumor cells. Although several acquired resistance mechanisms have been reported …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling - PubMed - 6 month(s) ago
Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare and resistance ultimately emerges from residual tumor cells. Although several acquired resistance mechanisms have been reported …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 43JCI Insight - MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF - 6 month(s) ago
ResearchIn-Press PreviewOncology Open Access | 10.1172/jci.insight.173688 Takahiro Utsumi,1 Yuki Shimizu,1 Ai Takemoto,1 Tomoko Oh-hara,1 Ken Uchibori,2 Sophia Subat-Motoshi,3 Hironori Ninomiya,3 Kengo Takeuchi,4 Makoto Nishio,2 Yasunari Miyazaki,5 and Ryohei Katayama1 1Cancer Chemotherapy Center,…
Source: insight.jci.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Time to shift the burden of proof for oncogene-positive cancer? - Nature Reviews Clinical Oncology - 6 month(s) ago
Rearrangements of the ALK gene have been associated with sensitivity to crizotinib and other kinase inhibitors with activity against ALK. The phase III PROFILE 1007 randomized study of crizotinib versus chemotherapy has demonstrated that crizotinib is superior to standard second-line chemotherapy in ALK-positive non-small-cell lung cancer.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling - 7 month(s) ago
Abstract. Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare and resistance ultimately emerges from residual tumor cells. Although several acquired resistance mechanisms have been reported at the time of disease progression, adaptative resistance mechanisms that contribute to residual diseases before the outgrowth of tumor cells with acquired resistance are less clear. For the patients who have progressed after TKI treatments, but do not demonstrate ALK/ROS1 kinase mutations, there is a lack of biomarkers to guide effective treatments. Herein, we found that phosphorylation of MIG6, encoded by the ERRFI1 gene, was downregulated by ALK/ROS1 inhibitors as were mRNA levels, thus potentiating EGFR activity to support cell survival as an adaptive resistance mechanism. MIG6 downregulation was sustained following chronic exposure to ALK/ROS1 inhibitors to support the establi
Source: aacrjournals.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 2Sign the Petition - 10 month(s) ago
Eliminate ABIMs MOC requirement
Source: www.change.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1A Functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes - PubMed - 10 month(s) ago
CRISPR/Cas9 gene editing represents a powerful tool for investigating fusion oncogenes in cancer biology. Successful experiments require that sgRNAs correctly associate with their target sequence and initiate double stranded breaks which are subsequently repaired by endogenous DNA repair systems yie …
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Newly published work @_LauraSchubert et al. We developed a rapid way to screen and induce CRISPR-based oncogenic gene fusions. We believe this technique will help generate multiple novel syngeneic models to aid in studying the role of immune therapies. https://t.co/TWaxqubpDu https://t.co/IN9AM0uR1E
-
-
Mashup Score: 0National DNA Day - 1 year(s) ago
National DNA Day commemorates the successful completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix in 1953.
Source: Genome.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1ERBB family fusions are recurrent and actionable oncogenic targets across cancer types - 1 year(s) ago
PurposeGene fusions involving receptor tyrosine kinases (RTKs) define an important class of genomic alterations with many successful targeted therapies now approved for ALK, ROS1, RET and NTRK gene fusions. Fusions involving the ERBB family of RTKs have been sporadically reported, but their frequency has not yet been comprehensively analyzed and functional characterization is lacking on many…
Source: FrontiersCategories: Hem/Oncs, Latest HeadlinesTweet
The Katayama lab arrived at Mig6 as a critical regulator of ALK/ROS1 resistance via a CRISPR screen whereas our lab arrived there via proteomics analysis. Clearly an important mediator of drug resistance. https://t.co/F66ENEUC4b